Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: Handling frequently accessed pages is disclosed. An indication is received of a stalling event caused by a requested portion of memory being inaccessible. It is determined that the requested portion of memory is a frequently updated portion of memory. The stalling event is handled based at least in part on the determination that the requested portion of memory is a frequently updated portion of memory.

Abstract: Systems, methods, and filter media for filtering molten aluminum or aluminum alloy are provided. The filter media includes a plurality of porous reticulated filter media pieces composed of at least one type of bonded particle. Each of the plurality of filter media pieces have a porosity between 5 pores per inch (PP) and 90 pores per inch and are between ¾ inches and 6 inches across and between ½ inches and 2 inches thick. The filter media pieces provide a plurality of external tortuous paths between the filter media pieces and a plurality of internal tortuous paths within individual ones of the filter media pieces for the molten aluminum or aluminum alloy to flow through when the filter media pieces are arranged in a filtration vessel. The filter media may be used in an inline deep bed aluminum filtration process to replace existing media.

Abstract: A user device may include a memory and a processor. The user device may send, via a cellular network, instructions to an unmanned aerial vehicle (UAV). The instructions may include instructions to capture a plurality of first images while the UAV is in flight. The user device may receive, while the UAV is in flight, one or more second images via a wireless wide area network. The one or more second images may be lower resolution versions of a subset of the first plurality of images. The user device may store the one or more second images at the user device.

Abstract: A re-useable partitioning seal used storage containers creates a virtually airtight chambers, to preserve products therein. A disc or differently shaped layer, with flat top and bottom surfaces, is configured to fit against the interior surface of a storage container. A thin, flexible perimeter forming a gasket around the layer, and a handle attached to the layer without fissure or cavity, thereby providing and a single piece, inexpensive re-useable partitioning seal.

Abstract: A user device may include a memory and a processor. The user device may send, via a cellular network, instructions to an unmanned aerial vehicle (UAV). The instructions may include instructions to capture a plurality of first images while the UAV is in flight. The user device may receive, while the UAV is in flight, one or more second images via a wireless wide area network. The one or more second images may be lower resolution versions of a subset of the first plurality of images. The user device may store the one or more second images at the user device.

Abstract: A re-useable partitioning seal used storage containers creates a virtually airtight chambers, to preserve products therein. A disc or differently shaped layer, with flat top and bottom surfaces, is configured to fit against the interior surface of a storage container. A thin, flexible perimeter forming a gasket around the layer, and a handle attached to the layer without fissure or cavity, thereby providing and a single piece, inexpensive re-useable partitioning seal.

Abstract: A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: A molten metal filtration apparatus is provided. The apparatus includes a filter chamber having a floor, a metal inlet, a metal outlet, and a wall surface adapted to be partitioned by at least one filter element having an open cell structure characterized by a plurality of interconnected voids. The filter element partitions the filter chamber. At least one heater device is provided at an elevation within the filtration chamber that is equal to or below the filter element.

Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: Process for preparing (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (formula I) or a salt thereof by reacting phenyl(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate or a similar derivative (formula 13) with (S)-pyrrolidin-3-ol (formula 14). Process for preparing phenyl(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate (formula 13) or a similar derivative by reduction of (R)-5-(2-(2,5-difluorophenyl) pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyrimidine (formula 11) to (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-amine (formula 12). Process for preparing (R)-2-(2,5-difluorophenyl)pyrrolidine(R)-2-hydroxysuccinate (formula 10) by treating (R)—N—((R)-1-(2,5-difluorophenyl)-3-(1,3-dioxan-2-yl)propyl)-2-methylpropane-2-sulfinamide (formula 19) with an acid and a reducing agent.

Abstract: The invention provides chimeric capture probes immobilizable via an L-nucleic acid tail that can bind to a complementary L-nucleic acid in an immobilized probe. The capture probes are useful for capturing a target nucleic acid from a sample. The L-nucleic acid in the tail of the capture probe bind to the complementary L-nucleic acid in the immobilized probe with similar affinity as would otherwise equivalent D-nucleic acids. However, the L-nucleic acid of the capture probe tail and immobilized probes do not form stable duplexes with D-nucleic acids present in the in the sample containing the target nucleic acid. Binding of nucleic acids in the sample directly to immobilized probe or to the tail of the capture probe is reduced or eliminated increasing the sensitivity and/or specificity of the assay.

Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: A re-useable partitioning seal used storage containers creates a virtually airtight chambers, to preserve products therein. A disc or differently shaped layer, with flat top and bottom surfaces, is configured to fit against the interior surface of a storage container. A thin, flexible perimeter forming a gasket around the layer, and a handle attached to the layer without fissure or cavity, thereby providing and a single piece, inexpensive re-useable partitioning seal.

Abstract: An apparatus includes a processor with first and second input ports and a memory operably coupled to the processor. The processor can detect streams of media samples at the input ports and determine, in response to the detection of the streams of media samples, a capture start time. The processor can also capture a first frame of a first stream of media samples beginning at the capture start time, and a first frame of a second stream of media samples beginning at a first time subsequent to the capture start time. The processor can also calculate a relative offset time based on the capture start time, the first time, and a rate associated with the second stream of media samples, and store, in the memory, an indication of an association between the captured first frame of the second stream of media samples and the relative offset time.

Abstract: A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: An apparatus includes a processor with first and second input ports and a memory operably coupled to the processor. The processor can detect streams of media samples at the input ports and determine, in response to the detection of the streams of media samples, a capture start time. The processor can also capture a first frame of a first stream of media samples beginning at the capture start time, and a first frame of a second stream of media samples beginning at a first time subsequent to the capture start time. The processor can also calculate a relative offset time based on the capture start time, the first time, and a rate associated with the second stream of media samples, and store, in the memory, an indication of an association between the captured first frame of the second stream of media samples and the relative offset time.

Abstract: A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.